May. 27 at 9:55 AM
$RNXT
https://empor.top/us/RNXT
Worth reading
“This article traces the company from a Silicon Valley garage and a cardiologist's "ah-ha" moment in the cath lab, through an Orphan Drug Designation, a 2021 micro-cap IPO, a positive interim analysis that the market mostly ignored, and into the strange purgatory of a sub-
$50 million market-cap biotech sitting on a Phase 3 readout that could either rerate the equity by an order of magnitude or extinguish it. Along the way we will examine the drug-device hybrid business model, the lean operating philosophy of a sub-twenty-person company running a global Phase 3 study, and the strategic question that hovers over every micro-cap in this space: is this a future acquisition target for big pharma, or is it a binary lottery ticket priced like one?”
